Please login to the form below

Not currently logged in
Email:
Password:

multiple myeloma

This page shows the latest multiple myeloma news and features for those working in and with pharma, biotech and healthcare.

FDA hands BMS and bluebird bio a priority review for ide-cel

FDA hands BMS and bluebird bio a priority review for ide-cel

The immunotherapy, idecabtagene vicleucel (ide-cel/bb2121), is designed to treat adult patients with relapsed and refractory myeloma. ... BMS and bluebird bio are aiming for approval of ide-cel in adult patients with multiple myeloma who have received

Latest news

More from news
Approximately 63 fully matching, plus 239 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    The antibody specialist company is riding high on the success of Darzalex, the multiple myeloma therapy which it has co-developed and co-marketed with J&J, and which is set

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    Its most important pipeline candidate, however, is the multiple myeloma targeting CAR-T therapy bb2121, being co-developed with Celgene.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow ... EvaluatePharma has predicted it could become a nearly $2.5bn

  • Deal Watch October 2018

    treatment of multiple myeloma and other conditions. Joint development. agreement. $665m. ... Who’s the winner? We won’t know for many years. Multiple deals from Gilead too.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    ASCO last year, and a larger, 1, 000-patient study across multiple cancers is due to report in 2020. ... The CAR-Ts have transformed the treatment of childhood ALL – an otherwise incurable blood cancer – and have been shown to work in hard-to-treat

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics